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Although intravascular stents have received widespread application, significant limitations remain. In stent restenosis, the
most pervasive problem affecting stents, is related in part to technical aspects of the device. Design features of the stent
that influence outcome have been identified and optimized for improved performance. The influence of stent materials on
critical aspects of healing, such as thrombotic, inflammatory, and hyperplastic responses, are less well understood. For this
reason, significant progress in this area is lacking. Current stents have significant contamination with industrial impurities
on the surface and in the bulk. This fact adds to the difficulties in interpreting the biologic reaction of the host to the
device. Better understanding of the basic biologic interactions is the path to significant improvement. (J Vasc Surg 2002;
36:1031-9.)
The mode of failure of contemporary implantable vas-
cular stents varies according to the final expanded diameter.
Large diameter devices, such as aortic stent grafts, are most
susceptible to corrosion that leads to degradation of me-
chanical integrity. Small-diameter and medium-diameter
stents, such as coronary and renal stents, respectively, are
prone to neointimal hyperplasia that leads to in stent reste-
nosis. Because of the large number of coronary stent pro-
cedures performed each year,1 in stent restenosis is by far
the most important limitation of these devices.
The patency of a stent depends on: 1, the clinical profile
of the host; 2, the characteristics of the target lesion; 3,
procedural factors; and 4, technical features of the stent,
including its design and material composition. Because the
engineering aspects of a stent can hopefully be controlled
and optimized, this review focuses on the analysis of current
data and work in progress in the area of stent design and
material composition.
Restenosis is the loss of the luminal diameter gain
obtained at the time of initial stent placement from neoin-
timal hyperplasia. The timing of its occurrence is similar to
other percutaneous coronary interventions. In stent reste-
nosis typically develops 1 to 3 months after stent place-
ment2,3 but may be progressive up to 18 months.4 The late
loss of the stent lumen from intimal hyperplasia was found
to be a constant proportion of the initial luminal gain.
Because stents produce the largest initial gain, compared
with balloon angioplasty and atherectomy, they have the
largest late loss.5 This finding is consistent with the fact that
a large increase in the lumen generally involves a high
degree of vessel wall damage, in turn producing a propor-
tionally large intimal hyperplastic response. The correlation
of the degree of stent-induced injury to the vessel wall, with
the extent of intimal hyperplasia, has been shown in exper-
imental models.6 Schwartz et al6 showed a close correlation
between the degree of penetration of the stent struts into
the layers of the vessel wall and intimal proliferation
measured as cross-sectional area. In human specimens ob-
tained at autopsy or after surgery, Farb et al7 confirmed a
relationship between injury and extent of intimal forma-
tion.
More recently, the degree of intimal hyperplasia has
been correlated with histologic evidence of inflammation in
the stented vessel. Acute inflammatory infiltrates of neutro-
phils are prevalent a few days after stent placement,7 and
macrophages and lymphocytes predominate 6 months after
stenting and later.8 However, granuloma formation has
been observed in the vicinity of the stent struts in stented
vessels with intimal hyperplasia, independent from the de-
gree of injury.9 Although inflammatory infiltrate has been
identified predominantly in stented vessels with medial
disruption and penetration of stent struts in the lipid core,8
some investigators have called attention to the role of
particulate contaminants of stents producing inflammation.
Whelan, van Beusekom, and van der Giessen10 identified
starch and fibers in tissues surrounding implanted stents,
and Bayes-Genis et al11 showed that pressure rinsing of
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stents before placement to remove particulate contami-
nants results in a reduction of intimal hyperplasia.
Kastrati et al12 recently reviewed restenosis risk factors
after coronary angioplasty and stenting. Increased risk for
restenosis was associated with clinical profile variables such
as diabetes mellitus and high blood pressure. Other clinical
risks for stent restenosis included the DD phenotype for the
angiotensin converting enzyme gene.13 An elevated fibrin-
ogen level is likely to increase the risk for stent restenosis
because it has been associated with increased failure rate of
vascular implants, as in lower extremity bypass proce-
dures.14 Lesion characteristics, such as small diameter
vessel, long lesions, ostial lesions, complex lesions, com-
plete occlusions, high-grade stenoses, and previously ste-
notic lesions, are all associated with an increased risk of
restenosis. Finally, procedural variables, such as placement
Fig 1. Human aortic EC migration onto 1  1-cm, 316L stainless steel flat coupons after fixation and Giemsa
staining. ECs were seeded and grown to confluence on ammonium cross-linked, firm collagen gel, covering rectangular
polyester film sheet. Thin (600 m) coupons then were implanted into endothelialized surface, such that top surface
was flush with gel surface. Entire sheet then was placed into parallel plate flow chamber and exposed to fluid-imposed
arterial level shear (15 dynes/cm2) on left or low shear (1.5 dynes/cm2) wall stress on right for 4 days. Arrow indicates
direction of flow. With high shear, all cell migration occurs in direction of flow. At low shear, migration is diminished
and in all directions.
Fig 2. Percentage of total area of surface obstacles covered by
ECs after 4 days with flow at 16 dynes/cm2. ECs were grown to
confluence on polyester film sheet with attached pieces of polyester
film of increasing thickness serving as obstacles. Asterisks indicate
statistically significant difference compared with 25 m.
Fig 3. Human aortic ECs migrating on stainless steel in direction
of arrow. Confluent human aortic ECs were allowed to migrate
from firm collagen gel onto implanted 1 1-cm flat stainless steel
coupons with static culture conditions for 7 days. On encounter
with surface scratch, cells deviate to follow feature. Three cells in
middle of field are aligned on single scratch. Giemsa stain, 200.
JOURNAL OF VASCULAR SURGERY
November 20021032 Palmaz et al
of multiple stents and stent type, have a strong influence on
the procedural outcome.12 Among all of the currently
known risk factors, the technical aspects of the stent are the
most amenable to change. Optimization of stent design
and materials hopefully will lead to improved clinical re-
sults.
STENT DESIGN AND CLINICAL EXPERIENCE
Kastrati et al15 examined the clinical outcome in pa-
tients treated with five different designs of stainless steel
coronary stents and found significant differences in the
event-free survival rates at 1 year. Despite the many varia-
tions involved in the design of stents, their configuration
can be generally classified into slotted and coiled. Slotted
stents have the members disposed predominantly along the
longitudinal axis and are inherently rigid along this axis.
Coiled stents have the members disposed substantially per-
pendicular to the long axis and are therefore more flexible.
The introduction of perpendicular members into the de-
sign of stents to attain longitudinal flexibility results in
advantages inherent to ease of manipulation and enhanced
technical success. However, coiled stents seem to have a
lower patency rates in the long term. The coiled GRII stent
(Cook Inc, Bloomington, Ind) and the Wiktor stent
(Medtronic, Minneapolis, Minn) were compared with the
slotted Palmaz-Schatz stent (Cordis, J&J, Warren, NJ) in
patients with coronary artery disease and both were found
to have higher restenosis rates.16 A randomized study that
compared the GRII stent with the Palmaz-Schatz stent also
showed a higher restenosis rate for the former.17 Escaned et
al18 found that the restenosis rate in coiled stents was
double that in slotted stents. However, the differences
between slotted and coil stents have recently become
blurred because many current stents combine features of
slotted design, such as longitudinal members with trans-
verse elements to provide flexibility.
The plethora of balloon expandable stent designs in
clinical use today evolved from the original Palmaz and
Palmaz-Schatz slotted balloon expandable stents. The basic
function of the balloon expandable stent relies on a funda-
mental functional unit consisting of expanding rings joined
together in a variety of different ways. The mechanism of
action of the balloon expandable rings depends on plastic
deformation of the angle at which the struts connect,
imposed by the radial force of a balloon. In the traditional
slotted stent, these ring units are joined at the angles,
forming spaces or cells. Staggered cells constitute the mesh.
Overall, separating the rings apart and joining them at
alternate points or with various flexible connectors allows
the stent to attain longitudinal flexibility.
SURFACE TOPOGRAPHY AND STENT
ENDOTHELIALIZATION
Several factors influence the rate of coverage of a metal
surface with endothelium spreading from a proximal source
on a flat featureless surface. The rate of endothelial cell
(EC) coverage is influenced more by migration than by
proliferation.19 An important factor that affects the rate of
endothelialization is flow shear rate. In our laboratory, we
found that in static culture conditions, the rate of EC
migration on a metal surface such as stainless steel or nitinol
is initially 10m/h and increases to 15m/h 10 days later.
In the presence of flow at normal shear rates, the migration
Fig 4. Human aortic ECs migrating on uniformly scratched
stainless steel surface. Cells migrated from confluent human aortic
EC covered gel onto flat stainless steel coupons as described
previously. Parallel scratch pattern was created with 320-grain
carbide sand paper. Giemsa stain, 200.
Fig 5. Bars indicate mean number of ECs per mm2 on stainless
steel microfabricated surfaces, with square section grooves from 7
to 20 m wide. Grooves of defined width were created with
photolithographic process. Grooved stainless steel 1  1-cm cou-
pons were implanted on endothelialized gel surface as described
previously, and cells were allowed to migrate onto surface for 7
days with static culture conditions. Control indicates flat surface.
Surface with 15-m grooves has significantly larger cell popula-
tion.
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rate increases to 25 m/h by 7 days.19 With normal shear,
ECs migrate in the direction of flow with little migration
observed against flow. With low shear, migration is slower
and tends to occur in every direction (Fig 1). This obser-
vation agrees with the fact that coronary stents placed with
minimal injury to the endothelium may require only a few
days to endothelialize. In contrast, in stents placed in totally
occluded vessels or after large endothelial injury, such as
after catheter endarterectomy or laser revascularization,
endothelializaton time may be prolonged from several
weeks to a few months.
In addition to flow shear, the topography of the surface
plays a role in EC coverage. An obstacle raised above the
plane of the vessel’s inner surface, such as an intravascular
stent, hinders cell progression in a manner proportional to
its height. Because stents have complex geometries, an
experimental model of a stent was made with simple shapes
of flat material with a thickness commensurate with the
thickness of vascular stents. Pieces of progressively increas-
ing heights from 25 to 250m were placed on a monolayer
of ECs in a laminar flow chamber at physiologic wall shear
stress (15 dynes/cm2). The number of cells able to gain
access on top of the obstacles decreased significantly with
heights of 100 m and greater, compared with 25 m. No
cells were found on top of 250 m-thick obstacles20 (Fig
2). These experimental results agree with clinical experi-
ence with intravascular stents having increased failure rates
with increasing wall thickness. Kastrati et al21 studied two
coronary stents of identical design and wall thicknesses of
50 and 140 m and encountered significantly higher clin-
ical and angiographic restenosis rates with the later. This
reflects impaired endothelialization and increased intimal
Fig 6. Time of flight secondary ion mass spectrometry image of approved gold-coated coronary balloon expandable
stent. Image on left corresponds to total ion image. Images in middle and right correspond to gold and iron,
respectively. If gold coat had been continuous, no underlying element would be visible. Measuring bar is 10 m.
Fig 7. Atomic force microscopy, force-volume array images. Images are 32  32 pixels (50  50 m) of electropol-
ished stainless steel 316L (left) and same material, sputter coated with gold palladium (right). Yellow corresponds to
repulsive forces in mid range. Pink and dark brown correspond to strongly attractive and repulsive forces, respectively.
Electropolished steel has homogeneous charge distribution. Sputter-coated steel shows marked electrostatic surface
heterogeneity.
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formation with the larger obstacles caused by thicker stent
struts.
With slow motion video recordings of ECs migrating
on a flat surface under flow, we observed that cells migrate
downstream not in straight lines but rather in a zigzag
pattern. This motion increases the probability of encounter
with other migrating cells. Cell collisions reduce migration
speed by contact inhibition. Multiple collisions halt migra-
tion and allow confluence. If a migrating cell encounters a
linear feature on the surface, such as a scratch disposed at an
angle to the direction of flow, it follows the feature (Fig 3).
If multiple parallel scratches are made on the surface, the
cells migrate in straight lines along the scratches (Fig 4).
The migration speed is thus increased because the side to
side movement is inhibited.22 The increase in migration
speed reflected on the cell count on the leading edge of the
material is dependent on the width of the grooves, as it
relates to cell size (Fig 5). Narrow grooves prevent cell
progression, and excessively large grooves allow the cells to
wander, therefore slowing down migration speed. With
stents with microscopic parallel grooves created on the
inner surface, we found significantly accelerated endotheli-
alization rates in carotid artery stents of pigs 1 week after
placement.23 With the hypothetic assumption that no en-
dothelial damage is produced by the stent placement, ECs
adjacent to the raised stent struts slough because of super-
ficial microflow disturbances. This is shown experimentally
by measuring the area devoid of ECs shortly after place-
ment of geometric obstacles on an EC monolayer. The
angle of the sides of the object relative to the flow direction
influences the extent of endothelial slough. The lowest EC
loss is observed adjacent to the edges along the flow, and
the largest on the down flow side of edges disposed trans-
versely. Intermediate degrees of EC loss were found on the
transverse upstream edge and on the 45-degree edge.20
This finding supports the clinical experience of higher
restenosis rates for coiled stents with struts substantially
perpendicular to the direction of flow.18
The influence of the edge angle of stent struts in the
vertical axis (radial direction in a vessel lumen) also was
evaluated. Shallow angles in objects disposed perpendicular
to flow allowed the largest number of cells to migrate on
top of the obstacle.24 This observation indicates that stent
struts should have blunted edges or, even better, a trape-
zoidal cross section.
The density of the stent mesh has an influence on the
intimal hyperplastic response. Stents with few struts spaced
far apart produce more intimal hyperplasia than more struts
around the circumference if they are evenly distributed.
This is related to wall indentation with a few stent struts
producing a polygonal rather than a circumferential lu-
men.25 However, increased strut density may come at the
price of larger metal surface, and this in turn may affect
patency. Of course, the many variables influenced by stent
design, such as total metal surface, radiopacity, radial
strength, expandability ratio, shortening, and flexibility,
affect each other. Typically, compromises must be reached
to attain the best possible results within technical limita-
tions.
STENT MATERIAL COMPOSITION
Design advances outpace material developments in all
vascular prosthetic developments from stents to artificial
hearts.26 Unlike design features, the impact of the material
composition on the clinical performance of stents is difficult
to ascertain. Slow release of metal ions in the tissues sur-
rounding metal implants may be the reason for local inflam-
matory and hyperplastic responses observed with stents.
Corrosion products from alloys commonly used in the
fabrication of stents, such as stainless steel 316L and niti-
nol, exhibit biotoxicity.27,28 Nitinol has shown to have a
Fig 8. Differential interference contrast microscopy of approved nitinol stent. Focal defects in oxide layer appear as
discrete spots (arrows). 50.
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local inflammatory effect by causing increased monocyte
secretion of interleukin-1 .29
Cobalt, nickel, and chromium are all capable of induc-
ing a cutaneous hypersensitivity reaction.30-32 Interest-
ingly, Koster et al33 found a correlation between coronary
steel stent restenosis and contact dermatitis to nickel and
molybdenum. Kastrati et al34 and vom Dahl et al35 found
increased angiographic and clinical restenosis rates in gold-
coated stents compared with identical steel counterparts. In
our laboratory, time of flight secondary ion mass spectro-
scopic images of gold-coated stents showed evidence of
defects in the top gold layer, which may explain the poor
outcome (Fig 6). However, Edelman et al36 observed a
decrease in intimal hyperplasia and inflammation if gold-
electroplated steel stents were further treated with a baking
process. Reportedly, the thermal treatment seals the defects
of the plated gold layer and prevents the untoward tissue
response.
The presence of defects in a material coating another
material, both with different electric charges, may create
conditions for localized galvanic currents leading to corro-
sion and biologic interactions different from adjacent areas.
Gold’s separate position in the electromotive force series
from chromium and titanium explains such an occur-
rence.37 We have documented with imaging a marked
variability in the surface electric charge of steel sputter
coated with gold and palladium with atomic force micros-
copy force volume arrays.38 This provides objective evi-
dence of electric heterogeneity produced by the incomplete
coat (Fig 7). The surface oxide layer may be defective (Fig
8) or develop defects as a result of deformation of the stent.
If this happens, the bulk stent material is exposed and a
corrosion reaction may occur.
Several papers report advantages of nitinol39,40 versus
stainless steel in regards to decreased thrombogenicity.
However, we could not confirm such results in our labora-
tory. In ongoing work, we found stainless steel to have the
lowest thrombogenicity among other metals and alloys
commonly used for the manufacture of stents. However,
the coating of stents with nonmetallic materials has been
tried extensively in the pursuit to avoid real or perceived
limitations of metals as vascular implants. Unfortunately,
much of the experimental and clinical work on new coating
materials does not directly compare the modified stents
with bare metal controls. Coatings in general have potential
disadvantages relating to cracks and discontinuities, fluid
seepage, and delamination. Aside from the problems in
stability of the coating process, Van der Giessen et al41
found that covering steel stents with polymeric materials
resulted in marked inflammation with most polymers
tested. Coating metal stents with phosphoryl choline ap-
parently adds no significant advantage.42 Ceramic-like
coating, such as diamond-like films, was found to have no
significant advantages over bare metal stents.43 Silicon car-
bide44 and turbostratic carbon45 seem to be adequate
surface materials, but superiority over metal stents was not
proven. In comparison of stainless steel with frequently
used polymers and ceramic materials, we found that, except
for polyhydroxyethylmethacrylate, steel has the lowest
thrombogenic potential.
With the limitations of the current technology, the
widespread clinical use of stainless steel in stent manufac-
ture for the past 10 years seems to confirm the adequacy of
this material and its place as state-of-the-art material. Re-
ported clinical series of steel stents with 9 years of follow-up
attest to the durability of the device and give important
reassurance about sustained long-term benefit.46,47
Fig 9. Pie chart of surface atomic mass composition with radio-
graph photoelectron spectroscopic analysis of fracture surface of
medical-grade steel tubing in three stages of cold drawing. Top
graph corresponds to 10 mm-diameter tube; middle and bottom
graphs represent 6 mm-diameter and 2 mm-diameter tubes. As
diameter decreases, iron decreases markedly as sulfur and silicone
increase.
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CONTAMINANTS ON APPROVED STENTS
With surface-sensitive analysis, we found a significant
amount of unexpected chemicals on the surface of stents
approved for clinical use in the United States. The most
abundant material found was the lubricant polydimethylsi-
loxane.48 Polydimethylsiloxane is used in the extrusion of
plastic catheters and is omnipresent on the surface of deliv-
ery and balloon catheters. The material is transferred on
contact with the stent because of its large spreading capa-
bility. However, polydimethylsiloxane appears biologically
inert in vessels and does not seem to pose a disadvantage.
Stent manufacturers try to clean stents from polydimethyl-
siloxane and other contaminants remaining after process-
ing, and the result of this attempt may be additional depo-
sition of chemicals on the surface of the stent, such as
sodium. The sodium contamination was found with x-ray
photoelectron spectroscopy to be in the form of hydroxide
rather than any salt, pointing to the use of NaOH-contain-
ing cleaning agents.
The bulk material of stents also has significant contam-
inants, resulting from the industrial processing of the
wrought material in tubing, sheets, or wire form. For
example, multiple cold drawings and annealing of the tub-
ing material used for stent manufacture leave increasing
levels of residues from high pressure lubricants in the grain
boundaries (Fig 9).
Electropolishing of steel eliminates much of these con-
taminants, leaving resilient chromium oxide as the predom-
inant surface constituent. This may be the reason for the
improved healing response of vessels to electropolished
compared with nonpolished stents.49 However, surface
imaging of current stents, approved and ready for patient
implant, still shows significant impurities (Fig 10). The
result of this is chemical heterogeneity of the stent surface.
Chemical imaging of the surface reveals large heterogeneity
in the distribution of the main components of steel, such as
chromium and iron, and materials that are different from
the nominal composition. Because protein interaction with
metal surfaces depends on the physical and chemical prop-
erties of such surface, variability of the surface may result in
heterogeneous protein distribution. This in turn may result
in uneven cellular attachment and healing. It is therefore
possible that the lack of material surface uniformity in
current stents may account for unpredictable healing pat-
terns and procedural outcome.
Uneven bulk composition may also be responsible for
mechanical failure in large stent devices. Decreased nickel
concentration was observed at areas of structural failure
from corrosion in nitinol aortic stent grafts.50,51 Structural
failure of large stents, subjected to much larger strain
compared with small and medium stents, may be related to
focal heterogeneities and material inclusions leading to
galvanic corrosion and eventual fracture.
Because material contamination and heterogeneities
seem to be suspect for inadequate healing patterns and
material failure, it appears reasonable to emphasize the
need for improved materials, with homogenous composi-
tion at the molecular level and freedom from extraneous
chemicals on the surface and in the bulk. The use of
drug-eluding coatings is effective and seems reasonably
safe,52 but uncertainty about long-term results and cost
considerations make this approach debatable. Despite the
current paucity of information on the basic mechanisms of
interaction of the vessel wall with stents, new developments
should be aimed at improving currently used materials
rather than suppressing biologic responses that are not
completely understood.
Fig 10. Time of flight secondary ion mass spectrometry image of approved coronary balloon expandable stent. Iron
image (left) and chromium carbide image (right) of same spot. Spot is representative of whole stent and corresponds
to strut in center of device. Defects in iron image correspond to carbide deposits. Measuring bar is 10 m.
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